Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity
Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.
MedPage Today1mon
Selective Role for Single-Agent Ipilimumab After Anti-PD-1 Failure in Melanoma
About 40% of patients with metastatic melanoma respond to PD-1/L1 inhibition ... Cancer Network recommends single-agent pembrolizumab (Keytruda) or nivolumab (Opdivo), combination therapy with ...
Healthline7d
All About Keytruda
Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...
Cure Today5d
Keytruda Has Long-Term Survivorship Implications in Early Triple-Negative Breast Cancer
Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...
Business Insider19h
Medicenna announces single-agent activity of MDNA11 from dose expansion cohort
1 CR and 2 PRs among 11 patients with cutaneous melanoma. SD in 6 patients including 3 with duration ... Cohort 3: 120 microgram/kg Q2W MDNA11 and 400 mg Q6W KEYTRUDA; Cohort 4: 120 microgram/kg Q3W ...
STAT14d
Dreams of cancer vaccines are becoming more real. Here are 9 scientists making it happen
Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at ...
Melanoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
The leading Melanoma Companies such as IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics ...
Yahoo Finance1mon
Microbiotica initiates subject dosing in Phase Ib melanoma therapy trial
It will assess the safety, tolerability and initial efficacy of MB097 plus MSD’s (Merck & Co.) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with cutaneous melanoma who have not ...
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. -- Phase 1 ...
Why Is Moderna Stock Trading Higher On Monday?
On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal ...
Big chase for a cancer drug: The urgent need for affordable Keytruda alternatives
Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...
manilatimes1mon
Microbiotica Announces First Patient Dosed in its International Phase 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma
The MELODY-1 study will investigate the safety, tolerability, and initial signals of efficacy of MB097 in advanced (metastatic) melanoma, in combination with KEYTRUDA ® (pembrolizumab), MSD's (Merck & ...